XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
REVENUES:        
Total revenues $ 408,742 $ 476,784 $ 1,396,465 $ 1,408,338
OPERATING EXPENSES:        
Cost of sales 103,537 188,793 350,765 398,134
Research and development 157,869 147,053 467,701 471,449
Selling, general and administrative 183,333 179,450 541,812 542,157
Intangible asset amortization and contingent consideration 17,222 17,429 52,648 48,018
Gain on sale of nonfinancial assets 0 0 0 (59,495)
Total operating expenses 461,961 532,725 1,412,926 1,400,263
INCOME (LOSS) FROM OPERATIONS (53,219) (55,941) (16,461) 8,075
Equity in the income (loss) of BioMarin/Genzyme LLC 177 (921) (1,349) (1,077)
Interest income 1,827 4,004 8,737 13,539
Interest expense (3,870) (9,597) (11,491) (24,560)
Other income, net 8,925 1,239 11,788 1,886
INCOME (LOSS) BEFORE INCOME TAXES (46,160) (61,216) (8,776) (2,137)
Benefit from income taxes (9,666) (846,019) (2,594) (839,138)
NET INCOME (LOSS) $ (36,494) $ 784,803 $ (6,182) $ 837,001
NET INCOME (LOSS) PER SHARE, BASIC (in dollars per share) $ (0.20) $ 4.33 $ (0.03) $ 4.63
NET INCOME (LOSS) PER SHARE, DILUTED (in dollars per share) $ (0.20) $ 4.01 $ (0.03) $ 4.39
Weighted average common shares outstanding, basic (in shares) 183,214 181,142 182,616 180,592
Weighted average common shares outstanding, diluted (in shares) 183,214 197,674 182,616 194,959
COMPREHENSIVE INCOME (LOSS) $ (25,316) $ 765,138 $ 20,196 $ 827,222
Net product revenues        
REVENUES:        
Total revenues 393,840 460,741 1,348,279 1,368,816
Royalty and other revenues        
REVENUES:        
Total revenues $ 14,902 $ 16,043 $ 48,186 $ 39,522